Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2023
‘Asthma care in Korea reminds me of Canada 8 years ago’
3 July 2023 - Korean-born expert in Canada stresses appropriate reimbursement for biological drugs. ...
Posted by Michael Wonder on 03 Jul 2023
Novartis’ Scemblix gets benefit to treat chronic myeloid leukaemia third or more times
30 June 2023 - Novartis' Scemblix (asciminib) will receive reimbursement for the third-line or more treatment of chronic myeloid leukaemia ...
Posted by Michael Wonder on 28 Jun 2023
Korea’s drug pricing policies for the second half of 2023
22 June 2023 - In the first half of 2023, the Ministry of Health and Welfare set up a public ...
Posted by Michael Wonder on 14 Jun 2023
Oral SMA drug Evrysdi passes reimbursement review
2 June 2023 - The nation’s health insurance review agency said Roche's Evrysdi (risdiplam), an oral treatment for spinal muscular ...
Posted by Michael Wonder on 14 Jun 2023
Brukinsa gets reimbursement to treat rare blood cancer patients
2 May 2023 - Beigene Korea said Monday that its Brukinsa 80 mg capsules (zanubrutinib) began to receive insurance benefits ...
Posted by Michael Wonder on 01 Jun 2023
BMS Korea wins insurance coverage for myelofibrosis drug Inrebic
1 June 2023 - BMS Korea has announced that Inrebic (fedratinib), its myelofibrosis drug, will now be covered by the ...
Posted by Michael Wonder on 20 May 2023
SMA patients protest inconsistent reimbursement standards for Spinraza
19 May 2023 - Spinal muscular atrophy patients taking Spinraza (nusinersen sodium) are protesting against the Health Insurance Review and ...
Posted by Michael Wonder on 17 May 2023
Astellas seeks to expand reimbursement for prostate cancer drug Xtandi
16 May 2023 - Astellas Pharma has set about to rectify the reimbursement track for Xtandi (enzalutamide), its prostate cancer ...
Posted by Michael Wonder on 09 May 2023
Opdivo to get reimbursement soon as primary treatment of stomach cancer
9 May 2023 - Opdivo (nivolumab), an anti-PD-1 immunotherapy, will likely receive insurance benefits soon as the primary treatment of ...
Posted by Michael Wonder on 27 Apr 2023
Even drugs winning fast-track nods frustrate before reimbursement wall
27 April 2023 - Several targeted agents for lung cancer approved through fast-track review due to their innovativeness and urgency ...
Posted by Michael Wonder on 26 Apr 2023
Sales agent change gives red light to Gavreto’s reimbursement review
26 April 2023 - The changes in sales right for Gavreto (pralsetinib), an RET inhibitor, may likely negatively influence the ...
Posted by Michael Wonder on 05 Apr 2023
Global blockbusters’ failure to win insurance coverage raises questions about fairness
5 April 2023 - Here is a case in which patients' treatment options and companies' business rights have been put ...
Posted by Michael Wonder on 04 Apr 2023
Long-waited drugs were approved, but patients must wait for insurance benefits
4 April 2023 - Braftovi (encorafenib) is a targeted agent used for VRAF V600E mutant metastatic colorectal cancer patients with ...
Posted by Michael Wonder on 28 Mar 2023
'To develop digital health, separate insurance coverage system needed’
28 March 2023 - The Government needs to establish a separate reimbursement registration frame for digital treatment devices that secure ...
Posted by Michael Wonder on 06 Mar 2023
Will reimbursement criteria of SMA treatment Spinraza change?
6 March 2023 - The discussion will likely begin in earnest this month to expand reimbursement criteria for Spinraza (nusinersen ...